|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Prazosin#Pharmacology]] |
| {{Prazosin}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==CLINICAL PHARMACOLOGY==
| |
| | |
| The exact mechanism of the [[hypotensive]] action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Recent animal studies, however, have suggested that the vasodilator effect of prazosin is also related to blockade of postsynaptic alpha-adrenoceptors. The results of dog forelimb experiments demonstrate that the peripheral vasodilator effect of prazosin is confined mainly to the level of the resistance vessels (arterioles). Unlike conventional alpha-blockers, the [[antihypertensive]] action of prazosin is usually not accompanied by a [[reflex tachycardia]]. Tolerance has not been observed to develop in long term therapy.
| |
| | |
| Hemodynamic studies have been carried out in man following acute single dose administration and during the course of long term maintenance therapy. The results confirm that the therapeutic effect is a fall in blood pressure unaccompanied by a clinically significant change in cardiac output, heart rate, renal blood flow and [[glomerular filtration rate]]. There is no measurable negative chronotropic effect.
| |
| | |
| In clinical studies to date, prazosin hydrochloride has not increased plasma [[renin]] activity.
| |
| | |
| In man, blood pressure is lowered in both the supine and standing positions. This effect is most pronounced on the diastolic blood pressure.
| |
| | |
| Following oral administration, human plasma concentrations reach a peak at about three hours with a plasma half-life of two to three hours. The drug is highly bound to plasma protein. [[Bioavailability]] studies have demonstrated that the total absorption relative to the drug in a 20% [[alcoholic]] solution is 90%, resulting in peak levels approximately 65% of that of the drug in solution. Animal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man.
| |
| | |
| In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre- and post-treatment lipid levels.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MINIPRESS (PRAZOSIN HYDROCHLORIDE) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc | publisher = | date = | accessdate = 6 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |